Skip to main content Start main content

RCMI develops nanotechnology for prolonging retention of ocular drugs on corneal surfaces

12 Mar 2024

Research Results

Prof. WONG Man-sau, Director of the Research Centre for Chinese Medicine Innovation (RCMI) and Prof. LIU Juewen from the University of Waterloo, successfully developed a novel formulation for treating dry eye diseases using nanoparticles, aptamer-functionalised liposomes.

A key challenge in ocular drug delivery is the need to prolong the retention of drugs within the eyes. Cyclosporine A is a therapeutic agent for dry eye diseases. The aptamer-functionalised liposomes developed by the team could prolong the retention of Cyclosporine A on the corneal surface. Aptamer-functionalised liposomes are nanoparticles which have aptamers, a short nucleotide, on its surface that can bind to specific molecular targets with high affinity. The team discovered a aptamer that is capable of binding to the corneal surface for delivering Cyclosporine A loaded in liposomes. This can not only mitigate the adverse effects associated with the drug, but also augment its therapeutic efficacy in managing dry eye disease.

Related research works have been published in three esteemed journals. The study opens up new avenues for the future of nano-based drug delivery, enabling the treatment of ocular diseases via topical eye drops that deliver natural products, supplements and small molecules.

 

Read the full paper: https://www.sciencedirect.com/science/article/pii/S2319417023001221


Research Units Research Centre for Chinese Medicine Innovation

Your browser is not the latest version. If you continue to browse our website, Some pages may not function properly.

You are recommended to upgrade to a newer version or switch to a different browser. A list of the web browsers that we support can be found here